Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
$11.53
+2.3%
$11.52
$10.47
$29.12
$165.35M0.6476,176 shs80,787 shs
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
$5.59
$5.59
$3.11
$5.60
$955.06M1.153.29 million shs6 shs
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
$3.07
-1.0%
$2.84
$2.36
$4.92
$229.64M0.45754,565 shs3.01 million shs
Intersect ENT, Inc. stock logo
XENT
Intersect ENT
$28.24
$28.24
$15.92
$28.25
$954.91M1.45351,526 shs14,512 shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
+2.31%+6.66%+5.49%-15.96%-57.50%
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
0.00%0.00%0.00%0.00%0.00%
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
-0.97%+0.66%+4.07%+4.78%-28.60%
Intersect ENT, Inc. stock logo
XENT
Intersect ENT
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
4.3221 of 5 stars
3.83.00.03.72.71.70.6
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
1.8875 of 5 stars
0.00.00.03.60.60.83.1
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
2.5372 of 5 stars
1.03.00.04.22.01.70.6
Intersect ENT, Inc. stock logo
XENT
Intersect ENT
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
3.50
Strong Buy$20.0073.46% Upside
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
0.00
N/AN/AN/A
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
2.00
Hold$3.00-2.28% Downside
Intersect ENT, Inc. stock logo
XENT
Intersect ENT
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ATRS, XENT, OSUR, and ANIK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/19/2025
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingIn-Line ➝ In-Line$3.00 ➝ $3.00
5/12/2025
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$20.00 ➝ $19.00
4/17/2025
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$21.00
4/16/2025
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
$117.05M1.41$0.10 per share118.15$10.51 per share1.10
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
$183.98M5.19$0.13 per share43.89$1.03 per share5.43
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
$185.83M1.24$0.04 per share79.85$5.50 per share0.56
Intersect ENT, Inc. stock logo
XENT
Intersect ENT
$106.75M8.95N/AN/A($2.06) per share-13.71
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
-$56.38M-$3.88N/AN/AN/A-41.28%-7.22%-5.64%8/6/2025 (Estimated)
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
$46.29M$0.2423.2925.41N/A21.90%7.43%4.92%N/A
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
-$19.50M-$0.42N/AN/AN/A-19.77%-5.86%-5.20%8/5/2025 (Estimated)
Intersect ENT, Inc. stock logo
XENT
Intersect ENT
-$159.63M-$4.79N/AN/AN/A-161.94%-709.52%-48.18%N/A

Latest ATRS, XENT, OSUR, and ANIK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
-$0.15N/AN/AN/A$30.52 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
N/AN/AN/AN/AN/A
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
N/AN/AN/AN/AN/A
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
N/AN/AN/AN/AN/A
Intersect ENT, Inc. stock logo
XENT
Intersect ENT
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
N/A
5.73
4.53
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
0.10
3.08
2.87
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
N/A
12.34
10.94
Intersect ENT, Inc. stock logo
XENT
Intersect ENT
6.89
1.88
1.50

Institutional Ownership

CompanyInstitutional Ownership
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
91.53%
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
50.41%
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
93.50%
Intersect ENT, Inc. stock logo
XENT
Intersect ENT
92.47%

Insider Ownership

CompanyInsider Ownership
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
9.64%
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
5.90%
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
3.90%
Intersect ENT, Inc. stock logo
XENT
Intersect ENT
2.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
30014.34 million12.96 millionOptionable
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
201170.85 million160.77 millionOptionable
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
84074.80 million71.88 millionOptionable
Intersect ENT, Inc. stock logo
XENT
Intersect ENT
43333.81 million33.10 millionOptionable

Recent News About These Companies

Zee Ent. - Zee Entertainment Enterprises Share Price
Kiatnakin Bank PCL (KKP)
At the Intersection of Law & Policy
XENT Historical Data

Media Sentiment Over Time

Top Headlines

View All Headlines
Anika Therapeutics stock logo

Anika Therapeutics NASDAQ:ANIK

$11.53 +0.26 (+2.31%)
Closing price 07/14/2025 04:00 PM Eastern
Extended Trading
$11.52 0.00 (-0.04%)
As of 07/14/2025 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

Antares Pharma stock logo

Antares Pharma NASDAQ:ATRS

Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto-injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto-injectors; TLANDO to treat deficiency or absence of endogenous testosterone in adult males; and drug/device products for urologic oncology, immunology, and endocrinology. The company has strategic alliances and partnerships with Pfizer Inc., Idorsia Pharmaceuticals Ltd, Teva Pharmaceutical Industries, Ltd, and AMAG. Antares Pharma, Inc. was incorporated in 1979 and is headquartered in Ewing, New Jersey.

OraSure Technologies stock logo

OraSure Technologies NASDAQ:OSUR

$3.07 -0.03 (-0.97%)
Closing price 07/14/2025 04:00 PM Eastern
Extended Trading
$3.08 +0.01 (+0.16%)
As of 07/14/2025 07:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OraSure Technologies, Inc., together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of void urine samples; and microbiome laboratory testing and analytical services. In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Additionally, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is based in Bethlehem, Pennsylvania.

Intersect ENT stock logo

Intersect ENT NASDAQ:XENT

Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL, a steroid releasing implant to open the surgically enlarged sinus; PROPEL Mini, a releasing implant to treat patients undergoing frontal sinus surgery; and PROPEL Contour, a steroid releasing implant for the treatment of frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California.